Audit: QRS - Kiwi for Health & Longevity
Audit conducted on 19/08/2026 08:42 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol cells vs ER lines 369/371/381, time-to-effect vs ER line 430, benefit and risk tiers vs the ER Expected Benefits / Potential Risks & Side Effects headings, gates vs ER lines 322–343, all 11 markers vs the ER monitoring table (lines 464–474), cadence vs ER line 460, qualitative items vs ER lines 478–483. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s “⚠️ Conflicted” flags on blood pressure and cholesterol are carried through as “(conflicted)”; marker_2 and marker_11 keep the ER’s “No established target” wording. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Absolute contraindications stay in the stop gate, “Caution”/”Monitor” items stay in the interactions gate; no tier or certainty was shifted. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Stop items come only from the ER’s “Populations who should avoid Kiwi” sub-list; caution items only from the ER interaction bullets; nothing from Benefit-Modifying Factors or Risk-Modifying Factors was promoted into a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, author names, NCT identifiers or brand names (Actazin, Livaux, Zyactinase, Zespri) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Flat, declarative, evidence-first register throughout, matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | At-a-glance leads with what holds up, then names what is unresolved and the single real hazard. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Cells state doses and windows as trial facts (“The dose in nearly every positive trial”), not instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; cadence is phrased as a schedule of measurements, not a directive. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommend”, “advise”, “should” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to biomarker names and decision-gate thresholds where they are load-bearing; the at-a-glance is jargon-free. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a fragment or single clause; no item carries a citation or mechanism. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a reader who will run baseline labs and keep a bowel diary. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Daily two-fruit habit, cultivar selection and an 11-marker panel are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content depth (Act d 1 specific IgE, 24-hour urinary oxalate) is well beyond general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The conflicted cardiometabolic signals are labelled as such rather than sold, and the vitamin C benefit is scoped to those starting low. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “adverse events”, “complete spontaneous bowel movements”, “international normalised ratio” are used in the ER’s own register. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present byte-identical to [qrs_template] at lines 445, 491, 541, 572, 592, 618, 646, 650–652, 823, and the four tier labels in both the benefits and risks cards. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff of the extracted var names shows all 34 template vars present; the only additions are the repeatable marker_#_* (11 rows) and qualitative_item_# (6 items) instances the template defines as repeatable. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three <span website="..."> hooks, the disclaimer, the stylesheet link and all CSS are unchanged from the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped by this template is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard dose”, “Cultivar selection” and “Best time of day” are the ER’s own bold labels (ER lines 369, 371, 381); the monitoring row labels are the ER biomarker-table names verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels (“Stool frequency”, “Plasma vitamin C”, “Mood and vitality”) are lifted from the ER’s own sentence at line 430 rather than invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No codepoint in the emoji ranges occurs in the file; the ER’s “⚠️ Conflicted” markers are rendered as plain “(conflicted)”. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than transcribed: benefits and risks are heading-level fragments, gate items are stripped of trailing clauses, marker_2’s target is shortened from the ER wording, and no section was extended with additional cards or rows beyond the template. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the comment opens immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the descriptive text sits on line 2 before the opener. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, and it contains a colon; all other values are bare and trimmed. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: kiwi_2026-0825-0623_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0819-0827. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version only. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual file on disk: kiwi_2026-0825-0623_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Kiwi for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Kiwi for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/19/2026, matching qrs_creation_date: 2026-0819-0827. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block is structurally identical to the template; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four clauses map to ER conclusion lines 505 (laxation), 505 (vitamin C and mood), 507 (unresolved BP/cholesterol/sleep) and 509 (allergy). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to a separate sentence of the ER Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain wording throughout (“bowel movements”, “fibre supplements”, “vitamin C shortfall”); no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author or year is named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers other than “Two” as a dose count. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All four items come from the ER’s “Populations who should avoid Kiwi” sub-list (ER lines 340–343). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | 4 ER contraindication entries → 4 stop items, none added or dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 575–587: four <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “— absolute contraindication” and “— absolute contraindication pending allergy testing” tails are stripped, and the leading “Anyone with” is dropped from item 1. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “stage 4 or worse”, “(eGFR below 30 mL/min/1.73 m²)”, “above 5.5 mmol/L” and “24-hour urinary oxalate above 45 mg/day” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does name such populations and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one to the ER bullets at lines 322–336. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | 8 ER interaction bullets → 8 caution items; no overlap with the four stop items. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 595–608: eight <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mechanism sentence (“Additive potassium load risks hyperkalaemia…”, “Platelet aggregation falls about 15%…”) is stripped; only the drug-class label remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All ER example-drug parentheticals retained verbatim (spironolactone/amiloride/lisinopril/losartan; aspirin/clopidogrel/apixaban; fish oil/ginkgo/garlic/vitamin E; polyethylene glycol 3350/psyllium). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eight such interactions and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol bullets at lines 369, 371 and 381. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, cultivar and timing are the three bullets that change what a reader actually does; the remaining ER bullets are commentary on guidelines, competing approaches and subgroups. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three actionable aspects and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans are populated; no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Stool frequency, plasma vitamin C and mood/vitality — the three windows the ER states at line 430. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High (constipation relief), High (vitamin C repletion), Medium (mood and vitality); the respiratory-symptom window, a Low benefit, is folded into time_3_sub rather than given a slot. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct windows and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated from ER lines 430, 164, 166 and 478. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (Practical Considerations, line 430). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All 11 ER benefit headings are represented across the four tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 543–565). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading reduced to a fragment; the ER’s Magnitude: lines and mechanism paragraphs are entirely absent. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s parenthetical glosses (CSBM, LDL-C, HbA1c expansions) are stripped; the only parentheses left are the ER’s own “Conflicted” evidence flags, which items 1.2/1.3 require be preserved. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven ER risk headings are represented across the four tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 620–640). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading reduced to a fragment; no prevalence figures, relative risks or mechanism text carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence come from the ER Monitoring Protocol & Defining Success section (lines 458–474). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 11 ER table rows present, in ER order: plasma vitamin C, CSBM/week, ferritin, potassium, eGFR, hs-CRP, LDL-C and ApoB, HbA1c, blood pressure, 24-hour urinary oxalate, specific IgE to Act d 1. Targets and “Why” text match the ER. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 811–817 condense ER line 460, keeping baseline/4-week checks, the conditional potassium check, the 6–12 month interval and the warfarin INR rule. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the “Qualitative markers worth tracking alongside the labs” list at ER lines 476–483. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER bullets present verbatim as qualitative_item_1 through qualitative_item_6. |
Issues 19/08/2026 08:42
Pass rate 100.00%. No issues found.
Issues 19/08/2026 08:39
- 2.8 — Time-to-effect sub-lines restate labels:
time_1_sub(“Stool frequency and consistency change.”) andtime_2_sub(“Plasma vitamin C saturates.”) repeat their own labels at QRS lines 503 and 514, consuming space on a one-page sheet without adding information beyond the label and value.
Fixes 19/08/2026 08:39
- 2.8 — Time-to-effect sub-lines restate labels: Replaced
time_1_sub“Stool frequency and consistency change.” with “Consistency shifts alongside frequency; straining improved ahead of it in several trials.” andtime_2_sub“Plasma vitamin C saturates.” with “Marginal status moves into the saturating range; those already replete change little.”, so both sub-lines add ER-sourced information instead of repeating their labels.
Issues 19/08/2026 08:33
- 11.4 — Time-to-effect sub mismatched: [time_3_sub] (lines 525–527) states “Respiratory-symptom effects required four weeks of daily intake.”, which does not describe the cell’s own label “Mood and vitality” or its value “2 weeks”, unlike the parallel subs in cells 1 and 2.
Fixes 19/08/2026 08:33
- 11.4 — Time-to-effect sub mismatched: Rewrote [time_3_sub] from “Respiratory-symptom effects required four weeks of daily intake.” to “Mood and vitality shift; respiratory-symptom effects require four weeks.” so the sub describes the cell’s own “Mood and vitality” label and “2 weeks” value.